The DOI matches its Crossref record; 146 of the 147 references it cites were found in a registry or an index.
Aβ Oligomers – a decade of discovery
Open accessAbstract
Converging lines of evidence suggest that progressive accumulation of the amyloid β‐protein (Aβ) plays a central role in the genesis of Alzheimer’s disease, but it was long assumed that Aβ had to be assembled into extracellular amyloid fibrils to exert its cytotoxic effects. Over the past decade, data have emerged from the use of synthetic Aβ peptides, cell culture models, β‐amyloid precursor protein transgenic mice and human brain to suggest that pre‐fibrillar, diffusible assemblies of Aβ are also deleterious. Although the precise molecular identity of these soluble toxins remains unsettled, accumulating evidence suggests that soluble forms of Aβ are indeed the proximate effectors of synapse loss and neuronal injury. Here we review recent progress in understanding the role of soluble oligomers in Alzheimer’s disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“recent studies have shown that the soluble Aβ oligomers are more neurotoxic both in vitro and in vivo.5−8”
From Small Bifunctional Chelators That Do Not Disaggregate Amyloid β Fibrils Exhibit Reduced Cellular Toxicity (2014) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For the preformed Aβ42 fibrils, no significant cell toxicity was observed in either the absence or presence of Cu2+ (Figure 9, lanes 1 and 2), supporting the previously reported diminished toxicity of Aβ42 fibrils.5,7,54−56”
From Small Bifunctional Chelators That Do Not Disaggregate Amyloid β Fibrils Exhibit Reduced Cellular Toxicity (2014) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, recent in vivo studies have shown that soluble Aβ oligomers are more neurotoxic than amyloid plaques and most likely responsible for synaptic dysfunction and memory loss in AD.7–11”
From The effect of Cu2+ and Zn2+ on the Aβ42 peptide aggregation and cellular toxicity (2013) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“However, recent in vivo studies have shown that the soluble Aβ oligomers are possibly more neurotoxic than amyloid plaques,14–17 and are likely responsible for synaptic dysfunction and memory loss in AD patients and AD animal models.18–21”
From Bifunctional Compounds for Controlling Metal-Mediated Aggregation of the Aβ42Peptide (2012) · cites this paper as [19]
The cited source says what the claim attributes to it.
In the citing paper
“which was also shown to form neurotoxic soluble Aβ oligomers.18–20”
From Bifunctional Compounds for Controlling Metal-Mediated Aggregation of the Aβ42Peptide (2012) · cites this paper as [19]
The cited source says what the claim attributes to it.
In the citing paper
“This is confirmed by the decreased cell survival of 44±8% in presence of soluble Aβ42 oligomers (Figure 11, lane 2), supporting the increased neurotoxicity of Aβ42 oligomers versus Aβ42 fibrils.16,19”
From Bifunctional Compounds for Controlling Metal-Mediated Aggregation of the Aβ42Peptide (2012) · cites this paper as [19]
The cited source says what the claim attributes to it.
In the citing paper
“the Aβ42 peptide was employed in these studies because it was shown to form neurotoxic soluble Aβ oligomers.5,8,48”
From Small Bifunctional Chelators That Do Not Disaggregate Amyloid β Fibrils Exhibit Reduced Cellular Toxicity (2014) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769 · cited 4×
“…performance in a hippocampaldependent contextual fear conditioning assay, decreased spine density in the dentate gyrus, and impairment of long-term potentiation (LTP) at ages long before the first apparent detection of Ab dodecamer (Dineley et al. 2002; Jacobsen et al. 2006; Lesne et al. 2006).”
BackgroundInfluentialRetractedCorder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Self-citationTriple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064
Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876 · cited 3×
“The initial cleavage leading to amyloid b-protein (Ab) production is mediated by the aspartyl protease, b-secretase (also called b-amyloid cleaving enzyme-1, BACE-1), and occurs immediately N-terminal to the Ab domain, simultaneously generating APPsb and the membranetethered C-terminal fragment, C99 (Vassar et al. 199…”
Background
Flagged first, then by citations
1 of the 147 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Selkoe D. J., 2003, Annu. Rev. Pharmacol. Toxicol., 545
- Shankar G. M., 2007, Natural oligomers of the Alzheimer amyloid beta‐protein induce hippocampal synapse loss but can be neutralized by antibodies and small molecules, J. Neurosci.
Cited by
Sorted by citations
Items 801–900 of 1,010
Amyloid–β peptides time-dependent structural modifications: AFM and voltammetric characterization
Enache, T. A., Paquim, A.-M. C., & Oliveira‐Brett, A. M. (2016) · Analytica Chimica Acta · doi:10.1016/j.aca.2016.04.015 · Cited by 45
Conti, E., Gregori, M., Radice, I., Re, F. D., Grana, D., Re, F., Salvati, E., Masserini, M., Ferrarese, C., Zoia, C., et al. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2017.02.012 · Cited by 46
Kinetic analysis of the multistep aggregation pathway of human transthyretin
Sun, X., Dyson, H. J., & Wright, P. E. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1807024115 · Cited by 44
McInnes, L. E., Noor, A., Kysenius, K., Cullinane, C. M., Roselt, P. D., McLean, C., Chiu, F. C. K., Powell, A. K., Crouch, P. J., White, J. M., et al. (2019) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.8b03466 · Cited by 45
Sun, L., Sharma, A. K., Han, B.-H., & Mirica, L. M. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00376 · Cited by 46
Reduction of amyloid-beta levels in mouse eye tissues by intra-vitreally delivered neprilysin
Parthasarathy, R., Chow, K. M., Derafshi, Z., Fautsch, M. P., Hetling, J. R., Rodgers, D. W., Hersh, L. B., & Pepperberg, D. R. (2015) · Experimental Eye Research · doi:10.1016/j.exer.2015.06.027 · Cited by 44
Data-driven modeling of Alzheimer Disease pathogenesis
Anastasio, T. J. (2011) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2011.08.038 · Cited by 44
Development of retro-inverso peptides as anti-aggregation drugs for β-amyloid in Alzheimer's disease
Matharu, B., El‐Agnaf, O. M. A., Razvi, A., & Austen, B. (2010) · Peptides · doi:10.1016/j.peptides.2010.06.033 · Cited by 45
Recent developments in targeting protein misfolding diseases
Denny, R. A., Gavrin, L. K., & Saiah, E. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.01.089 · Cited by 48
Mormino, E. C. (2014) · Neuropsychology Review · doi:10.1007/s11065-014-9267-4 · Cited by 44
Uddin, M. S., Kabir, M. T., Rahman, M. M., Mathew, B., Shah, M. A., & Ashraf, G. M. (2020) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.13244 · Cited by 44
Amandine, E. B., & Marchalant, Y. (2015) · Aging and Disease · doi:10.14336/ad.2015.0617 · Cited by 43
Gonzalez‐Velasquez, F. J., & Moss, M. A. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04988.x · Cited by 43
Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: The Present and the Future
Ghidoni, R., Benussi, L., Paterlini, A., Albertini, V., Binetti, G. G., & Emanuele, E. (2011) · Neurodegenerative Diseases · doi:10.1159/000327756 · Cited by 44
Zabel, C., Nguyen, H. P., Hin, S. C., Hartl, D., Mao, L., & Klose, J. (2010) · Journal of Proteomics · doi:10.1016/j.jprot.2010.08.008 · Cited by 44
Biflavonoids as Potential Small Molecule Therapeutics for Alzheimer’s Disease
Thapa, A., & Chi, E. Y. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-18365-7_3 · Cited by 44
Structure of ring-shaped Aβ42 oligomers determined by conformational selection
Tran, L., Basdevant, N., Prévost, C., & Ha‐Duong, T. (2016) · Scientific Reports · doi:10.1038/srep21429 · Cited by 44
Misiti, F., Clementi, M. E., & Giardina, B. (2010) · Neurochemistry International · doi:10.1016/j.neuint.2010.01.002 · Cited by 44
Herukka, S.-K., Rummukainen, J., Ihalainen, J., von und zu Fraunberg, M., Koivisto, A. M., Nerg, O., Puli, L. K., Seppälä, T. T., Zetterberg, H., Pyykkö, O. T., et al. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-142862 · Cited by 43
Hirohata, M., Ono, K., Takasaki, J.-I., Takahashi, R., Ikeda, T., Morinaga, A., & Yamada, M. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.05.006 · Cited by 43
Neuropathology of the Alzheimer's continuum: an update
Jellinger, K. A. (2020) · Free Neuropathology · doi:10.17879/freeneuropathology-2020-3050 · Cited by 52
Rahman, A., Saikia, B., Gogoi, C. R., & Baruah, A. (2022) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2022.08.007 · Cited by 43
Abelein, A., Bolognesi, B., Dobson, C. M., Gräslund, A., & Lendel, C. (2011) · Biochemistry · doi:10.1021/bi201745g · Cited by 45
McMains, V. C., Myre, M. A., Kreppel, L. K., & Kimmel, A. R. (2010) · Disease Models & Mechanisms · doi:10.1242/dmm.004457 · Cited by 43
Aβ 42 /Aβ 40 Ratios of Presenilin 1 Mutations Correlate with Clinical Onset of Alzheimer’s Disease
Tang, N., & Kepp, K. P. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180829 · Cited by 43
A dopamine metabolite stabilizes neurotoxic amyloid-β oligomers
Cataldi, R., Chia, S., Pisani, K., Ruggeri, F. S., Xu, C. K., Šneideris, T., Perni, M., Sarwat, S., Joshi, P., Kumita, J. R., et al. (2021) · Communications Biology · doi:10.1038/s42003-020-01490-3 · Cited by 42
RNA Aptamer Probes as Optical Imaging Agents for the Detection of Amyloid Plaques
Farrar, C. T., William, C. M., Hudry, E., Hashimoto, T., & Hyman, B. T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089901 · Cited by 46
Therapeutic insights elaborating the potential of retinoids in Alzheimer’s disease
Behl, T., Kaur, D., Sehgal, A., Singla, R. K., Makeen, H. A., Albratty, M., Alhazmi, H. A., Meraya, A. M., & BUNGAU, S. G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.976799 · Cited by 43
Ansciaux, E., Burtéa, C., Laurent, S., Crombez, D., Nonclercq, D., Elst, L. V., & Müller, R. N. (2014) · Contrast Media & Molecular Imaging · doi:10.1002/cmmi.1626 · Cited by 43
Llado-Saz, S., Atienza, M., & Cantero, J. L. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.06.023 · Cited by 43
Townsend, M., Qu, Y., Gray, A. J., Wu, Z., Seto, T., Hutton, M., Shearman, M. S., & Middleton, R. E. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.163691 · Cited by 42
Colombo, R., Carotti, A., Catto, M., Racchi, M., Lanni, C., Verga, L., Caccialanza, G., & Lorenzi, E. D. (2009) · Electrophoresis · doi:10.1002/elps.200800377 · Cited by 44
Hou, Y., Wang, Y., Zhao, J., Li, X., Cui, J., Ding, J., Wang, Y., Zeng, X., Ling, Y., Shen, X., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111215 · Cited by 43
Wısnıewskı, T., & Sadowski, M. J. (2008) · BMC Neuroscience · doi:10.1186/1471-2202-9-s2-s5 · Cited by 42
Chaudhary, H., Stefanovic, A. N. D., Subramaniam, V., & Claessens, M. M. A. E. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.10.016 · Cited by 42
Li, H., Du, Z., Lopes, D. H. J., Fradinger, E. A., Wang, C., & Bitan, G. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200982p · Cited by 43
McIntee, F. L., Giannoni, P., Blais, S. P., Sommer, G., Neubert, T. A., Rostagno, A. A., & Ghiso, J. A. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00223 · Cited by 42
Drug discovery using induced pluripotent stem cell models of neurodegenerative and ocular diseases
Hung, S. S. C., Khan, S., Lo, C. Y.-W., Hewitt, A. W., & Wong, R. C. B. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.026 · Cited by 47
Alzheimer’s disease: amyloid-based pathogenesis and potential therapies
Zhou, Y., Sun, Y., Ma, Q., & Liu, Y. (2018) · Cell Stress · doi:10.15698/cst2018.07.143 · Cited by 45
Sex Differences in Alzheimer’s Disease: Where Do We Stand?
Medeiros, A. D. M., & Silva, R. H. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180213 · Cited by 42
Andrade‐Talavera, Y., Arroyo‐García, L. E., Chen, G., Johansson, J., & Fisahn, A. (2020) · The Journal of Physiology · doi:10.1113/jp279718 · Cited by 38
Abnormal kalirin signaling in neuropsychiatric disorders
Remmers, C. L., Sweet, R. A., & Penzes, P. (2013) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2013.12.006 · Cited by 45
Porcellotti, S., Fanelli, F., Fracassi, A., Sepe, S., Cecconi, F., Bernardi, C., Cimini, A., Cerù, M. P., & Moreno, S. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/967203 · Cited by 41
Ubhi, K. K., Rockenstein, E. M., Doppler, E., Mante, M., Adame, A., Patrick, C., Trejo, M., Crews, L. A., Paulino, A., Moessler, H., et al. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0505-4 · Cited by 45
Kaminski, C. F., & Schierle, G. S. K. (2016) · Neurophotonics · doi:10.1117/1.nph.3.4.041807 · Cited by 42
MicroRNA group disorganization in aging
Lanceta, J., Prough, R. A., Liang, R., & Wang, E. (2009) · Experimental Gerontology · doi:10.1016/j.exger.2009.12.009 · Cited by 41
Pérez, J. L. M., Carrero, I., Gonzalo, P., Arévalo‐Serrano, J., Anquela, J. M. S., Ortega, F. J., Rodríguez, M. J., & Gonzalo‐Ruiz, A. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.10.013 · Cited by 44
Wise-Scira, O., Xu, L., Perry, G. L., & Coskuner‐Weber, O. (2012) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-012-0909-9 · Cited by 42
White matter microstructural changes in pure Alzheimer's disease and subcortical vascular dementia
Kim, Y. J., Kwon, H., Lee, J. ‐., Kim, Y. J., Kim, Y. J., Jung, N., Kim, S. T., Lee, K., Na, D. L., & Seo, S. W. (2015) · European Journal of Neurology · doi:10.1111/ene.12645 · Cited by 41
Tikhonova, M. A., Shoeva, O. Y., Tenditnik, M. V., Ovsyukova, M. V., Akopyan, A. A., Dubrovina, N. I., Amstislavskaya, T. G., & Хлесткина, Е. К. (2020) · Nutrients · doi:10.3390/nu12123877 · Cited by 43
Grinevich, V., Kolleker, A., Eliava, M., Takada, N., Takuma, H., Fukazawa, Y., Shigemoto, R., Kuhl, D., Waters, J., Seeburg, P. H., et al. (2009) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2009.07.015 · Cited by 40
Studies on Bacterial Inclusion Bodies
de Groot, N. S., Espargaró, A., Morell, M., & Ventura, S. (2008) · Future Microbiology · doi:10.2217/17460913.3.4.423 · Cited by 40
Basi, G. S., Feinberg, H., Oshidari, F., Anderson, J., Barbour, R., Baker, J., Comery, T. A., Diep, L., Gill, D. S., Johnson‐Wood, K., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.045187 · Cited by 45
From Soluble A β to Progressive A β Aggregation: Could Prion‐Like Templated Misfolding Play a Role?
Eisele, Y. S. (2013) · Brain Pathology · doi:10.1111/bpa.12049 · Cited by 43
Holm, P. C., Ettrup, A., Klein, A. B., Santini, M. A., El-Sayed, M., Elvang, A. B., Stensbøl, T. B., Mikkelsen, J. D., Knudsen, G. M., & Aznar, S. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100117 · Cited by 40
A Lifespan Observation of a Novel Mouse Model: In Vivo Evidence Supports Aβ Oligomer Hypothesis
Zhang, Y., Lu, L., Jia, J., Jia, L., Geula, C., Pei, J.-J., Xu, Q., Qin, W., Liu, R., Li, D., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085885 · Cited by 40
Li, X., & Zhang, Z. (2015) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12391 · Cited by 45
Effects of Sesaminol Feeding on Brain Aβ Accumulation in a Senescence-Accelerated Mouse-Prone 8
Katayama, S., Sugiyama, H., Kushimoto, S., Uchiyama, Y., Hirano, M., & Nakamura, S. (2016) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.6b01237 · Cited by 40
Replica exchange molecular dynamics study of the amyloid beta (11–40) trimer penetrating a membrane
Ngô, S. T., Hung, H. M., Tran, K. N., & Nguyen, M. T. (2017) · RSC Advances · doi:10.1039/c6ra26461a · Cited by 40
Cellular prion protein targets amyloid-β fibril ends via its C-terminal domain to prevent elongation
Bove‐Fenderson, E., Urano, R., Straub, J. E., & Harris, D. A. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.789990 · Cited by 42
Kannaian, B., Sharma, B., Phillips, M. F., Chowdhury, A., Manimekalai, M. S. S., Adav, S. S., Ng, J. T. Y., Kumar, A., Lim, S., Mu, Y., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-48819-5 · Cited by 41
Amyloid Evolution: Antiparallel Replaced by Parallel
Zanjani, A. A. H., Reynolds, N. P., Zhang, A., Schilling, T., Mezzenga, R., & Berryman, J. T. (2020) · Biophysical Journal · doi:10.1016/j.bpj.2020.03.023 · Cited by 40
Kravenska, Y., Nieznańska, H., Nieznański, K., Lukyanetz, E. A., Szewczyk, A. M., & Koprowski, P. (2020) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2020.183337 · Cited by 39
Fatty Acid Amide Hydrolase (FAAH) Inhibition Modulates Amyloid-Beta-Induced Microglia Polarization
Grieco, M., Caris, M. G. D., Maggi, E., Armeli, F., Coccurello, R., Bisogno, T., D’Erme, M., Maccarrone, M., Mancini, P., & Businaro, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147711 · Cited by 39
Autophagy and Diabetic Encephalopathy: Mechanistic Insights and Potential Therapeutic Implications
Cheng, L., Li, W., Chen, Y., Lin, Y., & Miao, Y. (2022) · Aging and Disease · doi:10.14336/ad.2021.0823 · Cited by 41
Therapeutic approaches for prion and Alzheimer's diseases
Wısnıewskı, T., & Sigurdsson, E. M. (2007) · FEBS Journal · doi:10.1111/j.1742-4658.2007.05919.x · Cited by 41
Lindberg, H., Härd, T., Löfblom, J., & Ståhl, S. (2015) · Biotechnology Journal · doi:10.1002/biot.201500131 · Cited by 39
Catalytic antibodies to amyloid β peptide in defense against Alzheimer disease
Taguchi, H., Planque, S. A., Nishiyama, Y., Szabo, P., Weksler, M. E., Friedland, R. P., & Paul, S. (2008) · Autoimmunity Reviews · doi:10.1016/j.autrev.2008.03.004 · Cited by 40
An Azobenzene Photoswitch Sheds Light on Turn Nucleation in Amyloid-β Self-Assembly
Doran, T. M., Anderson, E. A., Latchney, S. E., Opanashuk, L. A., & Nilsson, B. L. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn2001188 · Cited by 40
Lecanemab preferentially binds to smaller aggregates present at early Alzheimer's disease
Fertan, E., Lam, J. Y. L., Albertini, G., Dewilde, M., Wu, Y., Akingbade, O. E. S., Böken, D., English, E. A., Strooper, B. D., & Klenerman, D. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70086 · Cited by 39
Atomic-level investigations on the amyloid-β dimerization process and its driving forces in water
Chong, S., & Ham, S. (2011) · Physical Chemistry Chemical Physics · doi:10.1039/c2cp23326f · Cited by 39
Truong, P. M., Man, V. H., Nguyen, P. H., Hu, C., & Li, M. S. (2014) · The Journal of Physical Chemistry B · doi:10.1021/jp503652s · Cited by 39
Phenylpropanoids and Alzheimer's disease: A potential therapeutic platform
Kolaj, I., Liyanage, S. I., & Weaver, D. F. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2018.08.001 · Cited by 39
Fišar, Z., Jirák, R., Zvěřová, M., Setnička, V., Habartová, L., Hroudová, J., Vaníčková, Z., & Raboch, J. (2019) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2019.04.003 · Cited by 39
Aboulhoda, B. E., Rashed, L. A., Ahmed, H. R., Obaya, E. M. M., Ibrahim, W., Alkaffas, M., El‐Aal, S. A. A., & ShamsEldeen, A. M. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30283 · Cited by 39
Ceyzériat, K., Zilli, T., Fall, A. B., Millet, P., Koutsouvelis, N., Dipasquale, G., Frisoni, G. B., Tournier, B. B., & Garibotto, V. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.03.008 · Cited by 36
Solito, R., Corti, F., Fossati, S., Mezhericher, E., Donnini, S., Ghiso, J. A., Giachetti, A., Rostagno, A. A., & Ziche, M. (2008) · Experimental Cell Research · doi:10.1016/j.yexcr.2008.11.002 · Cited by 38
King, M., Nafar, F., Clarke, J.-P. W. E., & Mearow, K. M. (2009) · Journal of Neuroscience Research · doi:10.1002/jnr.22145 · Cited by 39
Li, X., Uemura, K., Hashimoto, T., Nasser-Ghodsi, N., Arimon, M., Lill, C. M., Palazzolo, I., Krainc, D., Hyman, B. T., & Berezovska, O. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.10.002 · Cited by 38
The role of RGC degeneration in the pathogenesis of glaucoma
Si, Z., Fan, Y., Wang, M., Zhao, J., Zhang, Y., Liu, D., & Zheng, Y. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.103222 · Cited by 46
Sitkiewicz, E., Kłoniecki, M., Poznański, J. T., Bal, W., & Dadlez, M. (2014) · Journal of Molecular Biology · doi:10.1016/j.jmb.2014.05.015 · Cited by 39
Panza, F., Frisardi, V., Imbimbo, B. P., Seripa, D., Solfrizzi, V., & Pilotto, A. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.579099 · Cited by 38
Adav, S. S., Gallart‐Palau, X., Tan, K. H., Lim, S. K., Tam, J. P., & Sze, S. K. (2016) · Molecular Brain · doi:10.1186/s13041-016-0200-z · Cited by 38
Replica exchange molecular dynamics study of the truncated amyloid beta (11–40) trimer in solution
Ngô, S. T., Hung, H. M., Truong, D. T., & Nguyen, M. T. (2016) · Physical Chemistry Chemical Physics · doi:10.1039/c6cp05511g · Cited by 38
Rafii, M. S., Skotko, B. G., McDonough, M. E., Pulsifer, M. B., Evans, C. L., Doran, E. W., Muranevici, G., Kesslak, P. J., Abushakra, S. R., Lott, I. T., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-160965 · Cited by 41
Targeting neurodegeneration to prevent post-traumatic epilepsy.
Ali, I., Silva, J. C., Liu, S., Shultz, S. R., Kwan, P., Jones, N. C., & O'Brien, T. J. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.08.006 · Cited by 38
Jürgenson, M., Zharkovskaja, T., Noortoots, A., Ma, M., Герович, Б. А., Zapolski, M., & Zharkovsky, A. (2019) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.13165 · Cited by 40
Fagiani, F., Lanni, C., Racchi, M., & Govoni, S. M. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.635880 · Cited by 43
Advances on the Understanding of the Origins of Synaptic Pathology in AD
Lacor, P. N. (2007) · Current Genomics · doi:10.2174/138920207783769530 · Cited by 40
Roses, A. D. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.153 · Cited by 37
Ostapchenko, V. G., Beraldo, F. H., Guimarães, A. L. S., Mishra, S., Guzmán, M. S., Fan, J., Martins, V. R., Prado, V. F., & Prado, M. A. M. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12296 · Cited by 38
Tailoring of Membrane Proteins by Alternative Splicing of Pre-mRNA
Mittendorf, K. F., Deatherage, C. L., Ohi, M. D., & Sanders, C. R. (2012) · Biochemistry · doi:10.1021/bi3007065 · Cited by 38
Increase in β-Amyloid Levels in Cerebrospinal Fluid of Children with Down Syndrome
Englund, H., Annerén, G., Gustafsson, J., Oxelgren, U. W., Wiltfang, J., Lannfelt, L., Blennow, K., & Höglund, K. (2007) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000109215 · Cited by 38
Amyloid Aggregation and Liquid–Liquid Phase Separation from the Perspective of Phase Transitions
Zhang, Z., Huang, G., Song, Z., Gatch, A. J., & Ding, F. (2023) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.3c01426 · Cited by 37
Tinker, C. L., Mayes, J., Allsop, D., & Kolosov, O. (2014) · Scientific Reports · doi:10.1038/srep04004 · Cited by 37
Lynx1 and Aβ1–42 bind competitively to multiple nicotinic acetylcholine receptor subtypes
Thomsen, M. S., Arvaniti, M., Jensen, M. M., Shulepko, M. A., Dolgikh, D. A., Pinborg, L. H., Härtig, W., Lyukmanova, E. N., & Mikkelsen, J. D. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.06.009 · Cited by 37
Aβ-Immunotherapeutic strategies: a wide range of approaches for Alzheimer's disease treatment
Montoliu‐Gaya, L., & Villegas, S. (2016) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2016.11 · Cited by 39
Sanchez‐Bezanilla, S., Nilsson, M., Walker, F. R., & Ong, L. K. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00181 · Cited by 37
Cytotoxic species in amyloid-associated diseases: Oligomers or mature fibrils
Siddiqi, M. K., Malik, S., Majid, N., Alam, P., & Khan, R. H. (2019) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2019.06.001 · Cited by 38
Prediction of AChE-ligand affinity using the umbrella sampling simulation
Lan, N. T., Vu, K. B., Ngoc, M. K. D., Tran, P., Hiệp, Đ. M., Tùng, N. T., & Ngô, S. T. (2019) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2019.107441 · Cited by 35
Metadata
- Authors
- Walsh, D. M., & Selkoe, D. J.
- Affiliations
- University College Dublin (IE)
- Brigham and Women's Hospital (US)
- Corresponding author
- Walsh, Dominic M.
- Selkoe, Dennis J.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2007-01-04
- Volume
- 101
- Issue
- 5
- Pages
- 1172-1184
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W1981458288
- Cited by
- 1,938
- References
- 147
- Citations by year
- 2026: 48 · 2025: 36 · 2024: 46 · 2023: 47 · 2022: 50 · 2021: 63 · 2020: 76 · 2019: 81 · 2018: 81 · 2017: 109 · 2016: 120 · 2015: 136 · 2014: 134 · 2013: 159 · 2012: 167
- FWCI
- 14.23
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Neurochemistry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Foundation for Neurologic Diseases
- Wellcome Trust (067660)
- National Institutes of Health
- National Institute on Aging (AG-06173)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid-beta oligomers, Alzheimer's disease, soluble amyloid-beta, synaptic loss, neuronal injury, amyloid fibrils, amyloid precursor protein, transgenic mouse model
- MeSH terms
- Alzheimer Disease, Humans, Male, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Protein Structure, Secondary
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
